Cytomel (Liothyronine) Cost in California 2026

California Retail Pricing Breakdown

The average cash-pay price for generic liothyronine at California retail pharmacies sits at $35 per month in 2026, based on a standard 25 mcg daily dose dispensed as a 30-count supply. Brand-name Cytomel from Pfizer carries a wholesale acquisition cost (WAC) of $120 per month. That gap makes the generic the default dispensing choice at most California chains. Liothyronine received FDA approval in 1956 under NDA 010379, and generic competition has been available for decades [1].

Prices vary by pharmacy. Costco and independent pharmacies in Los Angeles and San Francisco metro areas often price generic liothyronine between $28 and $38 for 30 tablets at the 25 mcg strength. CVS and Walgreens locations tend to cluster near the $35 median. The American Thyroid Association (ATA) guidelines note that liothyronine may be trialed in patients with persistent hypothyroid symptoms despite adequate levothyroxine dosing [2]. This clinical indication drives steady demand in California, where an estimated 2.1 million adults carry a hypothyroidism diagnosis according to CDC BRFSS data [3].

Patients filling at 90-day supply intervals can reduce per-unit cost further. Mail-order pharmacies licensed in California routinely offer 90-tablet supplies of liothyronine 25 mcg for $80 to $95, cutting monthly effective cost to $27 to $32.

Medi-Cal Coverage and Prior Authorization

Medi-Cal, California's Medicaid program, covers liothyronine with prior authorization (PA). The PA requirement exists because the Medi-Cal formulary classifies levothyroxine (T4) as first-line therapy for hypothyroidism, consistent with ATA/AACE 2012 guidelines [4]. Prescribers must document inadequate response to levothyroxine monotherapy or provide a clinical rationale for combination T4/T3 therapy.

PA approval typically requires: a documented TSH within reference range on stable levothyroxine for at least 6 weeks, persistent symptoms (fatigue, cognitive complaints, cold intolerance), and absence of alternative diagnoses explaining residual symptoms. The Endocrine Society clinical practice guideline acknowledges that a subset of hypothyroid patients report improved well-being on combination therapy [4]. Once approved, the PA is valid for 12 months and renewable.

For Medi-Cal beneficiaries, the out-of-pocket cost after PA approval is $0 to $1 per prescription under the state's nominal copay structure. Managed Medi-Cal plans (e.g., L.A. Care, Health Net) follow the same formulary tier but may have slightly different PA forms. The CMS Medicaid Drug Rebate Program ensures that the state receives manufacturer rebates on covered prescriptions [5].

Compounded Liothyronine: Legality and Cost in California

Compounded liothyronine T3 is legal in California through 503A pharmacies operating under the oversight of the California State Board of Pharmacy. Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding with a valid prescription [6]. California does not impose additional state-level restrictions beyond federal 503A requirements.

The typical cost for compounded liothyronine in California is $40 per month. Compounding pharmacies offer flexible dosing (e.g., 7.5 mcg, 10 mcg, 12.5 mcg capsules) that commercial tablets cannot provide. This matters clinically. The Bunevicius et al. (1999) trial in the New England Journal of Medicine used a 12.5 mcg dose of liothyronine as partial T4 replacement, a strength unavailable commercially [7].

Patients choosing compounded liothyronine should verify their pharmacy holds a current California Board of Pharmacy license and complies with USP 795 standards. The FDA's compounding quality page provides consumer guidance on evaluating compounding facilities [8]. Sustained-release compounded T3 formulations are available at some California pharmacies, though the ATA 2014 guidelines note limited evidence supporting sustained-release T3 over immediate-release formulations [2].

Insurance Coverage Beyond Medi-Cal

Commercial insurance plans in California generally cover generic liothyronine on Tier 1 or Tier 2, with copays ranging from $5 to $20 per month. Brand Cytomel, when specifically requested, falls on Tier 3 (preferred brand) or non-formulary, pushing copays to $40 to $75. Most plans require generic substitution unless the prescriber writes "dispense as written" (DAW) with clinical justification.

Covered California marketplace plans (Silver and above) include liothyronine on their Essential Health Benefits drug formulary. The ACA essential health benefits benchmark mandates prescription drug coverage in all qualified health plans [9]. Kaiser Permanente Northern and Southern California formularies list generic liothyronine without step therapy requirements, though PA may apply for doses exceeding 50 mcg daily.

Blue Shield of California and Anthem Blue Cross both list generic liothyronine at Tier 1. Patients on high-deductible health plans (HDHPs) pay cash price until meeting their deductible. For these patients, manufacturer savings programs and pharmacy discount cards become relevant. A 2020 JAMA Internal Medicine analysis found that 25% of prescriptions cost less with cash discount programs than through insurance [10].

Telehealth Access in California

California permits telehealth prescribing of liothyronine without geographic restriction. Senate Bill 803 and subsequent pandemic-era legislation cemented audio-video visit parity for prescribing controlled and non-controlled medications. Liothyronine is not a controlled substance, so no DEA-specific telehealth constraints apply.

Telehealth platforms operating in California can prescribe liothyronine after a synchronous clinical evaluation (video or phone), review of recent thyroid labs (TSH, free T4, and optionally free T3), and assessment of clinical appropriateness. The California Medical Board telehealth guidance confirms that standard-of-care requirements apply identically in virtual and in-person settings [11].

HealthRX offers California-licensed physician consultations with lab review and, where clinically appropriate, liothyronine prescriptions shipped to California addresses. Typical turnaround from consultation to pharmacy fill is 24 to 72 hours.

Discount Programs and Savings Strategies

Several pathways reduce out-of-pocket cost below the $35 average.

GoodRx and similar aggregators. GoodRx coupons bring generic liothyronine 25 mcg (30 tablets) to $12 to $18 at participating California pharmacies. These coupons function as cash-discount cards and cannot be combined with insurance.

Pfizer Savings Card. For brand Cytomel specifically, Pfizer offers a co-pay card that can reduce out-of-pocket costs to $0 to $25 for commercially insured patients. The card is not valid for Medi-Cal, Medicare Part D, or other government program beneficiaries.

RxAssist and NeedyMeds. These patient assistance databases connect uninsured or underinsured Californians with manufacturer programs and charitable foundations [12].

Mark Cuban Cost Plus Drugs. Generic liothyronine is available through cost-plus transparent pricing models at roughly $8 to $12 for 30 tablets, shipped to California addresses. This represents the lowest available price point for most uninsured patients.

90-day fills. Requesting 90-day supplies cuts dispensing fees and often yields a 15% to 20% discount versus three sequential 30-day fills. The FDA supports extended-day supply prescribing for stable chronic medications [13].

Clinical Context: Who Needs Liothyronine?

Liothyronine is synthetic triiodothyronine (T3), the active thyroid hormone. Most hypothyroid patients do well on levothyroxine (T4) alone, which the body converts to T3 via deiodinase enzymes. However, a subset of patients reports persistent symptoms despite normalized TSH. The Wiersinga et al. 2012 European Thyroid Association guideline estimates this group at 5% to 10% of treated hypothyroid patients [14].

The landmark Bunevicius et al. 1999 crossover trial (N=33) found that substituting 12.5 mcg liothyronine for 50 mcg levothyroxine improved mood, neuropsychological function, and patient preference compared to levothyroxine monotherapy [7]. Subsequent larger trials (e.g., Saravanan et al. 2005, N=697) showed mixed results on composite outcomes but confirmed patient preference for combination therapy [15].

The ATA 2014 guidelines suggest a trial of combination therapy may be considered for patients with persistent symptoms, using a T4:T3 ratio between 13:1 and 20:1, mimicking physiologic secretion [2]. At a typical replacement ratio, this translates to 5 to 15 mcg liothyronine daily alongside reduced-dose levothyroxine.

Dosing and Monitoring Considerations

Standard liothyronine dosing starts at 5 mcg daily, titrated by 5 mcg increments every 1 to 2 weeks based on clinical response and labs. The FDA-approved labeling recommends starting doses of 25 mcg daily for hypothyroidism, though modern endocrine practice favors lower initiating doses when used as adjunct therapy [1].

Monitoring should include TSH, free T4, and free T3 measured as a trough (pre-dose) at minimum 4 weeks after any dose change. Peak T3 levels occur 2 to 4 hours post-dose, and the short half-life of 6 to 8 hours necessitates twice-daily dosing in many patients to avoid symptomatic peaks and troughs [15]. Cardiac patients and those over 65 require slower titration. The ACC/AHA guidance on thyroid hormone use cautions against supraphysiologic T3 levels due to atrial fibrillation risk [16].

California patients starting liothyronine via telehealth should plan for repeat labs at 4 to 6 weeks post-initiation. Quest Diagnostics and Labcorp operate over 500 draw sites across California, and most offer free T3 panels at $35 to $50 cash-pay or covered under insurance preventive lab benefits.

How California Compares to Other States

California's $35 average cash price for generic liothyronine sits near the national median of $33 to $38. States with higher pharmacy operating costs (New York, Massachusetts) trend $3 to $5 higher. States with pharmacy benefit manager (PBM) transparency laws, including California under AB 315, have seen modest downward pressure on generic drug pricing [17].

California's Medicaid coverage with PA mirrors most other large states (Texas, Florida, Illinois). Where California differs is in compounding pharmacy access: the state's large network of licensed 503A pharmacies means patients outside major metro areas still have compounding options via mail order within state lines. The National Association of Boards of Pharmacy reports California has over 400 active compounding pharmacy licenses [18].